


**SUCCESS STORY**



CBmed's agile development cycle for translating research findings into innovative therapies, in collaboration with industry partners, leveraging foundational core technologies. Copyright CBmed

**Project 1.22/ Austrian COMET K1 Centre for Biomarker Research (CBmed)**

Programme: COMET – Competence Centers for Excellent Technologies

Programme line: COMET-Centre K1

Type of project: Multi-parameter core technologies, duration, 01.01.2019 – 31.12.2023, strategic

# DEVELOPMENT OF MULTI-OMICS TECHNOLOGIES TO TRANSLATE NEW APPROACHES IN CANCER THERAPY FASTER INTO NEW DRUGS

CBMED HAS DEVELOPED AND STANDARDISED MULTI-OMICS TECHNOLOGIES THAT CAN SERVE AS BASE FOR FUTURE COLLABORATIONS WITH PHARMACEUTICAL INDUSTRY TO ACCELERATE THE DEVELOPMENT OF FIRST-IN-CLASS DRUGS AND THERAPIES

In the realm of personalized medicine, precision and innovation are paramount. Thanks to the invaluable support provided by COMET funding, the K1 center CBmed has strategically cultivated an extensive portfolio of cutting-edge technologies and unparalleled expertise in the field of precision medicine. For CBmed the main success factor lies in bridging the realms of academic research and industry standards in analytics, fostering a shared understanding of the needs within the

pharmaceutical and analytical industry. In project 1.22, the primary emphasis centered on establishing standardized technologies for the cellular analysis of immune cells, tumor cells, and the tumor microenvironment. This encompassed the integration of cytometric technologies, microscopy, and advanced data science for comprehensive analysis. The outcome was a robust portfolio extended to the industry, featuring highly standardized protocols and comprehensive documentation, ensuring a valuable

## SUCCESS STORY

and reliable resource for collaborative ventures. Moreover, Project 1.22 employed a multidisciplinary team comprising experts in medicine, biology, and computer science. This collaborative initiative operated in close conjunction with various academic institutions affiliated with CBmed's stakeholders, fostering a rich and diverse collaborative environment.

Drawing upon their respective pools of expertise and advanced technologies, CBmed and Boehringer Ingelheim have started a groundbreaking collaboration in the realm of precision medicine (read the [press release](#)). This partnership is poised to play a pivotal role in shaping the landscape of the next decade, underscoring the significance of their joint efforts in advancing the frontiers of medical innovation. From the outset, CBmed and Boehringer

Ingelheim shared a common vision: to harness the power of biomarkers to tailor medical treatments to individual patients. This shared vision served as the catalyst for a partnership that would ultimately redefine the possibilities of personalized medicine.

### Impact and effects

Looking ahead, CBmed remains committed to pushing the boundaries of personalized medicine, with its partnership with Boehringer Ingelheim serving as a shining example of what is possible when visionary organizations unite in pursuit of a common goal. Together, they will continue to forge new paths, unlock new discoveries, and ultimately transform the future of healthcare for generations to come.

---

Project coordination (Story)	CBmed GmbH
Barbara Prietl, PhD	Stiftingtalstraße 5
CBmed GmbH	8010 Graz
T +43 316 385 28806	T +43 316 385 28801
barbara.prietl@cbmed.at	office@cbmed.at
	www.cbmed.at

### Project partners

- Medical University of Graz, Austria
- Graz University of Technology, Austria

This success story was provided by CBmed GmbH and by the mentioned project partners for the purpose of being published on the FFG website. CBmed is a COMET Centre within the COMET – Competence Centers for Excellent Technologies Programme and funded by BMK, BMDW, Steirische Wirtschaftsförderung GmbH (SFG) and Wirtschaftsagentur Wien (WAW). The COMET Programme is managed by FFG. Further information on COMET: [www.ffg.at/comet](http://www.ffg.at/comet)